Your browser doesn't support javascript.
loading
Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis.
Miao, Ji; Ling, Alisha V; Manthena, Praveen V; Gearing, Mary E; Graham, Mark J; Crooke, Rosanne M; Croce, Kevin J; Esquejo, Ryan M; Clish, Clary B; Vicent, David; Biddinger, Sudha B.
Afiliación
  • Miao J; Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Ling AV; Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Manthena PV; Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Gearing ME; Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Graham MJ; Isis Pharmaceuticals, Carlsbad, California, USA.
  • Crooke RM; Isis Pharmaceuticals, Carlsbad, California, USA.
  • Croce KJ; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Esquejo RM; Metabolic Disease Program and Diabetes and Obesity Center, Sanford-Burnham Medical Research Institute, Orlando, Florida, USA.
  • Clish CB; Broad Institute, Cambridge, Massachusetts, USA.
  • Vicent D; 1] Department of Endocrinology and Nutrition, Hospital Carlos III, Madrid 28029, Spain [2] Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid 28046, Spain.
  • Biddinger SB; Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Nat Commun ; 6: 6498, 2015 Apr 07.
Article en En | MEDLINE | ID: mdl-25849138
ABSTRACT
Despite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 (Fmo3) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro, increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oxigenasas / ARN Mensajero / Hepatocitos / Diabetes Mellitus Tipo 2 / Aterosclerosis / Factores de Transcripción Forkhead / Obesidad Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oxigenasas / ARN Mensajero / Hepatocitos / Diabetes Mellitus Tipo 2 / Aterosclerosis / Factores de Transcripción Forkhead / Obesidad Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos